Get notified when OBX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Auditor expressed substantial doubt about the company's ability to continue as a going concern, with cash runway only into Q3 2026.
- Concentration (new) — Company is heavily dependent on a single product candidate, tilarginine (OBX-115), which has not received regulatory approval.
- Control (new) — Obsidian management will take over the combined company, with former Galera holders owning only ~1.29% and Obsidian controlling the board.
OBX (Galera/Obsidian merger) files 424B3 for ~$350M Series C preferred financing and reverse merger
Filed July 2, 2026 · ~1 min read
Key Changes
-
high
Galera Therapeutics is merging with Obsidian Therapeutics via a two-step merger, with Obsidian management taking over and former Galera holders owning only ~1.29% post-merger.
The Offering verify on EDGAR → -
high
Concurrent financing: Galera will sell Series C Non-Voting Convertible Preferred Stock for approximately $350.0 million, with net proceeds of $27.6M to Galera and $2.9M to Obsidian.
The Offering verify on EDGAR → -
high
GAAP net loss (bottom line) is $350M, driven by a $151.0M non-cash gain from extinguishment of royalty purchase liability; underlying operating loss was $2.5M.
Management's Discussion and Analysis verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade OBX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify